News

Retatrutide at ADA 2026: Triple-Agonist vs. Tir...

ADA 2026 may bring new retatrutide data, but head-to-head trials against tirzepatide are still missing. We examine what clinicians need to know about

Retatrutide at ADA 2026: Triple-Agonist vs. Tir...

ADA 2026 may bring new retatrutide data, but head-to-head trials against tirzepatide are still missing. We examine what clinicians need to know about

Tirzepatide Medicare Coverage: What July 1 Mean...

Medicare Part D will cover tirzepatide for weight loss starting July 1, 2025, expanding access for older adults. This article examines the policy's implications

Tirzepatide Medicare Coverage: What July 1 Mean...

Medicare Part D will cover tirzepatide for weight loss starting July 1, 2025, expanding access for older adults. This article examines the policy's implications

Retatrutide and Bone Health: Could the Triple-A...

Retatrutide's triple-agonist mechanism raises questions about bone protection versus semaglutide, but human data are absent. We examine what studies

Retatrutide and Bone Health: Could the Triple-A...

Retatrutide's triple-agonist mechanism raises questions about bone protection versus semaglutide, but human data are absent. We examine what studies

Tirzepatide First-Line Status: ACP Obesity Guid...

ACP's 2025 guidelines elevate tirzepatide to first-line obesity treatment. We examine dosing protocols, female-specific metabolic considerations, and unanswered questions in reproductive-age cohorts.

Tirzepatide First-Line Status: ACP Obesity Guid...

ACP's 2025 guidelines elevate tirzepatide to first-line obesity treatment. We examine dosing protocols, female-specific metabolic considerations, and unanswered questions in reproductive-age cohorts.

Tirzepatide and Lean Muscle Preservation in GLP...

Tirzepatide shows a modest improvement in lean-to-fat loss ratio versus GLP-1 monotherapy, but absolute muscle loss remains significant and female-specific data are sparse.

Tirzepatide and Lean Muscle Preservation in GLP...

Tirzepatide shows a modest improvement in lean-to-fat loss ratio versus GLP-1 monotherapy, but absolute muscle loss remains significant and female-specific data are sparse.

Tirzepatide vs. GLP-1: Why Telehealth Shifts to Dual-Action

Tirzepatide vs. GLP-1: Why Telehealth Shifts to...

Telehealth platforms are adopting tirzepatide and retatrutide for weight loss, citing higher efficacy than GLP-1 monotherapy, but female-specific data and long-term safety remain limited.

Tirzepatide vs. GLP-1: Why Telehealth Shifts to...

Telehealth platforms are adopting tirzepatide and retatrutide for weight loss, citing higher efficacy than GLP-1 monotherapy, but female-specific data and long-term safety remain limited.